Hill Steve, Hamblett Ian, Brady Samantha, Vasileukaya Sviatlana, Zuzuarregui Ibon, Martin Fiona
Procedure Team Manager, The Christie Hospital, Manchester.
Nuclear Medicine Clinical Technologist, The Christie Hospital, Manchester.
Br J Nurs. 2019 Oct 24;28(19):S10-S18. doi: 10.12968/bjon.2019.28.19.S10.
Central vascular access device (CVAD)-related sheaths, sometimes described as 'fibrin sheaths', may result in minor or significant sequelae, from persistent withdrawal occlusion (PWO) to infective sheaths associated with increased morbidity and mortality. The authors studied 179 patients who underwent isotope scans, where isotope was infused via the CVAD. Isotope was found to bind to the sheaths around the catheters of some patients. The amount of uptake was taken to be an extent to which a sheath had developed around the CVAD. The degree of uptake of isotope was categorised into three groups: low uptake, moderate uptake and high uptake. Patients were then followed up from the date the CVAD was inserted to 12 months after the date of the isotope scan, until the device was removed or to the date the patient died, to identify incidence of infection, thrombosis and PWO. PWO incidence in all levels of uptake was around 5-7%. Bloodstream infection (BSI) incidence for low uptake was 7% (9/130), moderate uptake 10% (3/30) and for patients with significant uptake 16% (3/19). Thrombosis for no uptake was less than 1% (1/130), moderate uptake 7% (2/30), and significant uptake had no incidence of thrombosis. Total complications: no uptake 15%, moderate uptake 23% and significant uptake 21%. This single-centre study showed that patients with isotope-highlighted sheaths experienced higher incidence of infective, thrombotic and total complications.
中心血管通路装置(CVAD)相关的鞘管,有时被描述为“纤维蛋白鞘”,可能会导致从持续性拔管阻塞(PWO)到与发病率和死亡率增加相关的感染性鞘管等轻微或严重的后遗症。作者研究了179例接受同位素扫描的患者,同位素通过CVAD注入。发现同位素与一些患者导管周围的鞘管结合。摄取量被视为CVAD周围鞘管形成的程度。同位素摄取程度分为三组:低摄取、中度摄取和高摄取。然后从插入CVAD之日起至同位素扫描日期后12个月对患者进行随访,直到装置移除或患者死亡,以确定感染、血栓形成和PWO的发生率。所有摄取水平的PWO发生率约为5-7%。低摄取组的血流感染(BSI)发生率为7%(9/130),中度摄取组为10%(3/30),高摄取组患者为16%(3/19)。无摄取组的血栓形成发生率低于1%(1/130),中度摄取组为7%(2/30),高摄取组无血栓形成发生率。总并发症:无摄取组为15%,中度摄取组为23%,高摄取组为21%。这项单中心研究表明,同位素突出显示鞘管的患者发生感染、血栓形成和总并发症的发生率更高。